Psychedelic IPO Insights
Concerns about the rapid commercialization of psychedelics echo past mistakes, as industry players seek a more measured approach. A notable IPO from a biotech company highlights the potential for innovation in mental health, raising a significant amount of capital while navigating the complexities of drug development. This early-stage company is poised to make strides in addressing mental health needs, a critical area for many.In this clip
From this podcast
Equity
Tune in, SPAC on, drop LSD
Related Questions